Pediatric Emergency Transport | EB Medicine
EMPOWERING PHYSICIANS WITH EVIDENCE-BASED CONTENT
 

Home > Browse Topics

Pediatric Emergency Transport: Communication and Coordination Are Key to Improving Outcomes

 

Pediatric Emergency Transport: Communication and Coordination Are Key to Improving Outcomes

Facebook for Emergency Department Management of Patients With Thermal Burns (Trauma CME)Twitter for Emergency Department Management of Patients With Thermal Burns (Trauma CME)Linkedin for Emergency Department Management of Patients With Thermal Burns (Trauma CME)
 
  Issue Information

Authors: Abraham Gallegos, MD; Vijay Prasad, MD, MPH; Calvin G. Lowe, MD, FAAP

Peer Reviewers: Stephen Patterson, MD, FACEP; Kristy Williamson, MD, FAAP

Publication Date: April  1, 2018

CME Expiration Date: April 1, 2021

CME Credits: 4 AMA PRA Category 1 CreditsTM, 4 ACEP Category I Credits, 4 AAP Prescribed Credits, 4 AOA Category 2-A or 2-B Credits.

PubMed ID: 29565527

  About this Issue

This issue reviews the interfacility transfer process and discusses how coordination and preparedness can improve patient outcomes. In this issue, you will learn:

  • How to decide which patients require interfacility transfer
  • The roles of emergency clinicians involved in interfacility transfers and factors to consider when determining the composition of a transport team
  • The pros and cons of various transport modalities and how to decide which is most appropriate for your patient
  • What equipment and which medications are commonly used in interfacility transfers 
  • Which diagnostic studies should be performed at the referring facility and those that should be done during transport
  • Special considerations to take into account when transporting patients who are (or will be) extremely premature, those with hypoxic-ischemic injuries, ductal-dependent congenital heart disease, burns, and patients with special healthcare needs
  Issue Features
  Table of Contents
  1. Abstract
  2. Case Presentations
  3. Introduction
  4. Critical Appraisal of the Literature
  5. Interfacility Pediatric Transport Teams and Resources
    1. Transport Team Personnel
      1. Transport Physician
      2. Respiratory Therapist and Registered Nurse
    2. Communication Hub/Access Center
  6. Transport Modalities
    1. Ground Transportation
    2. Air Transportation
  7. Transport Equipment
  8. Transport Medications
  9. Diagnostic Studies
    1. Studies Conducted at the Referring Facility
    2. Studies Conducted During Transport
    3. Standardized Scoring Systems
  10. Treatment
  11. Special Considerations
    1. Extreme Prematurity
    2. Hypoxic-Ischemic Injury
    3. Ductal-Dependent Congenital Heart Disease
    4. Burns
    5. Patients With Special Healthcare Needs
  12. Controversies and Cutting Edge
    1. Transport Risk Scores
    2. Use of Surfactant
    3. Use of Inhaled Nitric Oxide
    4. Telemedicine
  13. Disposition
  14. Summary
  15. Risk Management Pitfalls When Planning the Transport of Pediatric Patients
  16. Time- and Cost-Effective Strategies
  17. Case Conclusions
  18. Clinical Pathway for Interfacility Transfer of Pediatric Patients: The Emergency Department Perspective
  19. Clinical Pathway for Interfacility Transfer of Pediatric Patients: The Transport Team Perspective
  20. Table
    1. Table 1. Common Medications and Intravenous Fluids Used During Transport
  21. References
  CME Information

Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.

Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Gallegos, Dr. Prasad, Dr. Lowe, Dr. Patterson, Dr. Williamson, Dr. Claudius, Dr. Horeczko, Dr. Mishler, and their related parties report no significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation. Dr. Jagoda made the following disclosures: Consultant, Daiichi Sankyo Inc; Consultant, Pfizer Inc; Consultant, Banyan Biomarkers Inc; Consulting fees, EB Medicine.

To view this issue, please choose one of the options below:

Purchase a
subscription
$319
Pediatric Emergency Medicine Practice
 
Purchase issue and
CME test (4 credits)
$39
Pediatric Emergency Medicine Practice
single issue
Sign up for a free trial
Free 48-hour trial
Pediatric Emergency Medicine Practice
 

2018 LLSA Testing Is Here

 
About EB Medicine:
Products:
Accredited By:
ACCME ACCME
AMA AMA
ACEP ACEP
AAFP AAFP
AOA AOA
AAP AAP
Endorsed By:
AEMAA AEMAA
HONcode HONcode
STM STM

 

Last Modified: 07/19/2018
© EB Medicine